Condition: Stage II Rectal Cancer · Organ Preservation · Non-operative Treatment · Sponsor: Sir Mortimer B. Davis - Jewish General Hospital
A randomized study of 131 patients. Patients with a clinical T2-3 N0-1 rectal cancer will be randomized to two arms (arm A: standard chemoradiation (45 Gy in 25 with concomitant 5-FU or Xeloda chemotherapy) and an external beam boost of 9 Gy compared to arm B: standard chemoradiation (45 Gy in 25 with concomitant 5-FU or Xeloda chemotherapy) and followed by a brachytherapy boost of 30 Gy in 3 fractions).
This description comes directly from the study's public registry record.
Susanne Knoepfel · 5143408288 · sknoepfel@jgh.mcgill.ca
Always discuss trial participation with your own doctor first.
| UT Southwestern Medical Center | Dallas, Texas, United States | Recruiting |
| Le Centre Hospitalier de l'Université de Montreal | Montreal, Quebec, Canada | Recruiting |
| Jewish General Hospital | Montreal, Quebec, Canada | Recruiting |
| Centre hospitalier universitaire de Québec | Québec, Quebec, Canada | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03051464